// App-Quantinova.ai

P216 : Effects of filgotinib on anaemia, thrombocytopoenia and leukopoenia: results from a Phase 3 study in patients with active RA and prior inadequate response or intolerance to bDMARDs

Researchers

Presenter

  • David Walker

Principal Investigators

  • Mark C Genovese

  • Kenneth Kalunian

  • Jacques-Eric Gottenberg

  • Beatrix Bartok

  • YingMeei Tan

  • Ying Guo

  • Chantal Tasset

  • John S Sundy

  • Kurt de Vlam

  • Tsutomu Takeuchi

Medical Centers

  • Rheumatology, Northumbria Healthcare NHS Foundation Trust, Newcastle upon Tyne, UNITED KINGDOM

  • Pediatrics, Urology, Stanford University, Palo Alto, CA

  • Cellular and Molecular Medicine, University of California San Diego, San Diego, CA

  • Rheumatology, Strasbourg University Hospital, Strasbourg, FRANCE

  • Epidemiology, Gilead Sciences, Foster City, CA

  • Clinical Pharmacology, Gilead Sciences, Inc., Foster City, CA

  • Biostatistics, Gilead Sciences, Inc, Foster City, CA

  • Rheumatology, Galapagos NV, Mechelen, BELGIUM

  • Inflammation and Respiratory Therapeutics, Gilead Sciences, Foster City, CA

  • Rheumatology, Universitair Ziekenhuis Leuven, Leuven, Belgium

  • Rheumatology, Keio University School of Medicine, Tokyo, JAPAN

Locations

  • United Kingdom

  • United States

  • France

  • Belgium

  • Japan

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Filgotinib

Outcome

  • N/A

Study Design

  • Randomized

  • Placebo Control

  • Double Blind/Blinded

Phase

  • III

Study Id's

  • NCT02873936

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved